ULTRAGENYX PHARMACEUTICAL INC. - COMMON STOCK

Ultragenyx to Participate in the Goldman Sachs 44th Annual Global Healthcare Conference

07 Jun 2023 16:00:00 By Nasdaq GlobeNewswire

Ultragenyx and Mereo BioPharma Announce Positive Data from the Ongoing Phase 2/3 Orbit Study of Setrusumab (UX143) in Osteogenesis Imperfecta (OI)

05 Jun 2023 15:00:53 By Nasdaq GlobeNewswire

Ultragenyx to Present at the 2023 Barclays - Gene Editing & Gene Therapy Summit

19 May 2023 07:30:00 By Nasdaq GlobeNewswire

Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

18 May 2023 16:00:00 By Nasdaq GlobeNewswire

Ultragenyx Receives FDA Agreement to Expand Ongoing Global Phase 1/2 Trial Evaluating GTX-102 in Patients with Angelman Syndrome in the U.S.

17 May 2023 07:00:01 By Nasdaq GlobeNewswire

Ultragenyx Announces Upcoming Data Presentations at American Society of Gene & Cell Therapy (ASGCT) 2023 Annual Meeting

08 May 2023 15:02:00 By Nasdaq GlobeNewswire

Ultragenyx to Present at Bank of America’s 2023 Health Care Conference

05 May 2023 15:01:00 By Nasdaq GlobeNewswire

Ultragenyx Reports First Quarter 2023 Financial Results and Corporate Update

04 May 2023 15:01:00 By Nasdaq GlobeNewswire

Dennis Huang of Ultragenyx Named to MassBio’s Board of Directors

28 Apr 2023 11:27:07 By Nasdaq GlobeNewswire

Ultragenyx to Host Conference Call for First Quarter 2023 Financial Results and Corporate Update

27 Apr 2023 15:05:00 By Nasdaq GlobeNewswire

Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

19 Apr 2023 15:01:00 By Nasdaq GlobeNewswire

Ultragenyx to Present at Guggenheim’s Genomic Medicines and Rare Disease Days

28 Mar 2023 15:01:00 By Nasdaq GlobeNewswire

Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

21 Mar 2023 07:30:00 By Nasdaq GlobeNewswire

Ultragenyx Appoints Dr. Eric Crombez Chief Medical Officer and Executive Vice President

14 Mar 2023 07:30:00 By Nasdaq GlobeNewswire

Ultragenyx to Participate in Orphan Neuro Panel at Cowen Healthcare Conference

28 Feb 2023 15:01:00 By Nasdaq GlobeNewswire

Ultragenyx Reports Fourth Quarter and Full Year 2022 Financial Results and Corporate Update

16 Feb 2023 15:01:00 By Nasdaq GlobeNewswire

Ultragenyx to Host Conference Call for Fourth Quarter and Full-Year 2022 Financial Results and Corporate Update

09 Feb 2023 15:01:00 By Nasdaq GlobeNewswire

Ultragenyx Reports Preliminary 2022 Revenue; Guidance for 2023 Revenue and Cash Usage; Pipeline Updates and 2023 Milestones

06 Jan 2023 15:01:00 By Nasdaq GlobeNewswire

Ultragenyx to Present at the 41st Annual J.P. Morgan Healthcare Conference

04 Jan 2023 05:00:00 By Nasdaq GlobeNewswire

Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

21 Dec 2022 15:01:00 By Nasdaq GlobeNewswire